



ORIGINAL ARTICLE

An Inclusive Disquisition on Thiazoles as Possible Antifungal Agents

Namrata N Mundargi¹, K Sujatha^{1,*}¹Department of Chemistry, Karnatak University, Dharwad, 580003, Karnataka, India

ARTICLE INFO

Article history:

Received 12.01.2025

Accepted 22.02.2025

Published 10.03.2025

* Corresponding author.

K Sujatha

drsujathak@kud.ac.in

[https://doi.org/](https://doi.org/10.61649/kujos/v56i1.24.sujatha)

10.61649/kujos/v56i1.24.sujatha

ABSTRACT

In recent years, antifungal medications have become increasingly ineffective due to antifungal resistance, which is one of the largest concerns facing the globe today. The inception of novel heterocycles that have substantial biological consequences has become vital owing to the advent of several epidemics and resistant bacteria. Numerous hybrid compounds are presently undergoing varying phases of clinical testing and could eventually be utilized in the therapeutic settings to address a range of ailments. In this overview, Nitrogen and sulfur-based heterocyclic aromatic compounds play a substantial and crucial role in medicine and the production of pharmacologically active substances. Thiazoles are highlighted for their crucial role, attributed to their wide array of biological activities within the field of medicinal chemistry. The emergence of antifungal resistance poses a considerable public health challenge as it diminishes the efficacy of antifungal treatments, leading to heightened rates of illness, mortality, and healthcare expenses. Given the foregoing, we have compiled an inventory of the most current developments in thiazoles as antifungal agents, encompassing papers reported from 2020 to 2024.

Keywords: Antifungal; Thiazoles

1 INTRODUCTION

In 1887, Hantzsch and Weber were the first to document thiazole, a heterocyclic compound with a five-membered ring containing both sulfur and nitrogen atoms. [1]

Heterocyclic compound with sulfur atom plays a key role in the drug discovery technique. One of these compounds is the thiazole ring. Thiazole, also known as 1,3-thiazole, is a pale-yellow flammable liquid characterized by a scent reminiscent of pyridine. Its molecular formula is C_3H_3NS , with a molecular weight of 85.128 g/mol, and it typically boils within the temperature range of 116–118°C. [2] Its aromatic nature arises from the delocalization of a lone pair of electrons originating from the sulfur atom, leading to the formation of a 6π -electron system. Furthermore, its pronounced aromaticity is evidenced by proton nuclear magnetic resonance, with the chemical shift values of each proton within the thiazole ring typically ranging between 7.27 and 8.77 ppm. [3] According to Hückel's rule, the density of the six π electrons indicates that electrophilic substitution primarily occurs at the C5 carbon, while nucleophilic substitution predominantly takes place at the C2 carbon. [4] Thiazole's reactivity, particularly because of

the acidic proton on its C2 position, makes it a versatile building block in organic synthesis. This reactivity allows for various functionalizations and transformations, leading to the creation of diverse chemical compounds with potentially valuable properties. Thiazole derivatives find applications in medicinal chemistry, agrochemicals, materials science, and more, contributing significantly to the development of new chemical entities with desired characteristics.




Figure 1: Thiazole

Thiazole exhibits aromaticity due to the delocalization of π -electrons across the five-membered ring system, including the sulfur atom. This delocalization, facilitated by resonance, stabilizes the molecule and contributes to its overall reactivity and properties. Thiazole's versatile reactivity allows it to

participate in a wide range of chemical reactions, including substitution, cycloaddition, oxidation, arylation, dimerization, and photochemical reactions, among others. [5] This reactivity arises from the presence of various functional groups that can be modified or transformed under suitable reaction conditions. The ability of thiazole to undergo such diverse reactions makes it a valuable building block in organic synthesis, enabling the construction of complex molecular structures and the development of novel chemical entities for various applications. Numerous novel chemical compounds with a wide spectrum of pharmacological properties have been produced as a result of these heterocycle alterations. [6] Many therapeutically authorized thiazole-containing drugs with a wide range of pharmaceutical properties are a reflection of its broad biological impact. Thiazole heterocycles serve as the bioactive core of numerous drugs, exhibiting a broad spectrum of pharmacological activities. Many thiazole-based compounds have shown efficacy as chemotherapeutic agents against various diseases, including cancer, fungal infections, bacterial infections, viral infections, and leishmaniasis. The chemical framework of thiazole is well recognized for its wide range of physiologically active properties. Numerous powerful pharmacologically active compounds, including the antibacterial drug Cefotaxime, the antifungal drug Isavuconazole, the antiviral drug Ritonavir, the antiparasitic drug Nitazoxanide, the anticancer drug Ixabepilone, the CNS drug Pramipexole, the gastrointestinal drug Nizatidine, the Cardio-vascular drug Amlodipine, the urinary infectious drug Mirabegron, the musculoskeletal drug Meloxicam, the musculoskeletal drug Febuxostat, and others typically include thiazoles. [7]




Figure 2: The Resonance Structure of Thiazole

The molecular composition of numerous natural products and physiologically active substances typically contains a thiazole molecule. Studies conducted on medicinal chemistry has shown that the thiazole molecules have an indispensable function in treating numerous kinds of illnesses. The broad-spectrum antifungal agent is abafungin. The fungicide and parasite i.e. thiabendazole, a novel DNA-binding gyrase B blocker. [8] Because of their excellent versatility in substitution placement i.e. substitutes can be incorporated at positions C-2, C-4, and C-5—thiazoles. Hence these frameworks are widely used in drug design [9–11]. Furthermore, the thiazole ring has garnered a lot of interest in agrochemical science due to the striking physiological functions of many thiazole derivatives. [12] It serves as a crucial element found in the structural framework of numerous naturally found, medicinally and physiologically active chemicals, including pharmaceuticals

that have been offered commercially, including bleomycin, pramipexole, febuxostat, vitamin B, ritonavir, penicillin-G, tiazofurin, abafungin, sulfathiazole, and sulfazole. [13]

The chemical study of thiazoles has currently been intensively developed due to the comparatively straightforward synthesis of a large range of compounds, allowing examining the relationship between their structure and characteristics. [14] Largazole, a thiazole-based natural product, was discovered to be a potent anticancer drug that works by inhibiting histone deacetylases (HDACs). [15] Dasatinib, dabrafenib, and apelsib are currently used to treat acute lymphoblastic leukemia, advanced melanoma, and breast cancer, respectively. Furthermore, the thiazole-based natural compounds patellamide A, ixabepilone, and epothilones possess clinical applications in the treatment of resistant prostate cancer, metastatic breast cancer, ovarian cancer, and rectal cancer. [8] The synthesis and design of azole-based heterocycles are of considerable interest because of their extensive applications in the pharmaceutical and agrochemical sectors for treating infections, diseases, and pests. [16] Thiazole moiety is commonly found in the structure of numerous natural products as well as physiologically active chemicals. Thiazole moiety has played an important role in medicinal chemistry research, with therapeutic effects against a variety of diseases. Thiazole moiety is commonly found in the structure of numerous natural products as well as physiologically active chemicals. Thiazole moiety has played an important role in medicinal chemistry research, with therapeutic effects against a variety of diseases. [17]

2 SYNTHESIS OF THIAZOLE DERIVATIVES

2.1 Hantzsch synthesis

Various synthetic methods of thiazole rings include 'Hantzsch synthesis' (Figure 3) methods because of its simplicity, which can incorporate various functional groups and has been most frequently used. This approach uses the condensation reaction of α -haloketone with nucleophilic reagents such thioamide, thiourea, ammonia thiocarbamate, or dithiocarbamate derivatives. [17]




Figure 3: Hantzsch synthesis of thiazole

2.2 Cook-Heilbron synthesis

Cook and Heilbron discovered the Cook-Heilbron synthesis (Figure 4), which involves reaction of α -aminonitriles or α -aminoamides with carbon disulfide to produce a thiazole ring. The Cook-Heilbron method established 5-aminothiazoles in which substitution happened at position 2 through the reaction of aminonitrile with salt and esters

of thioacids, carbon disulfide, or isothiocyanates under mild conditions. [18]




Figure 4: Cook-Heilbron synthesis of Thiazoles

2.3 Gabriel synthesis

Gabriel synthesis is another synthetic technique for producing thiazole compounds. The reaction of α -acylamino ketones or amino acetal with phosphorous pentasulfide yielded 2,5-disubstituted thiazoles in good yields (Figure 5). [19, 20]




Figure 5: Gabriel synthesis of Thiazoles

Condensation of equimolar mixture of thiourea and α -haloketones or aldehyde to produce 2-aminothiazole (Figure 6).




Figure 6: Synthesis of 2-aminothiazoles

2.4 Reactions with thioamides

Thioamides and α -halo carbonyl compounds were reacted to form thiazoles (Figure 7) with alkyl, aryl, arylalkyl, or heteroaryl functional groups at positions 2, 4, or 5. [21]




Figure 7: Synthesis of 2,4, or 5 substituted Thiazoles

The thiazole target compounds were synthesized via refluxing thiourea with aromatic ketone and Sodium Dichloriodate (NaICl_2).




Figure 8: 2-aminothiazoles synthesis

$\text{R} = \text{C}_6\text{H}_5, 4\text{-CH}_3\text{-C}_6\text{H}_4, 4\text{-NH}_2\text{-C}_6\text{H}_4, 4\text{-OCH}_3\text{-C}_6\text{H}_4$
Heravi et al. proposed a very effective method of synthesis. The reaction was completed at room temperature by grinding the appropriate amount of phenacyl bromide with thioacetamide in order to yield the designated 2,4-disubstituted Thiazoles.




Figure 9: 2,4-disubstituted Thiazoles synthesis

$\text{R} = \text{C}_6\text{H}_5, 4\text{-CH}_3\text{-C}_6\text{H}_4, 4\text{-NH}_2\text{-C}_6\text{H}_4, 4\text{-OCH}_3\text{-C}_6\text{H}_4$
A simple methodology for synthesizing thiazole-2-thiones from nitrobenzene, chalcones, and carbon disulfide is presented. In one pot, one C-S bond and two C-N bonds are formed using a [3+2] cycloaddition reaction with NaOH as the base. [22]




Figure 10: Synthesis of Thiazole-2-thiones

3 THIAZOLE DERIVATIVES AS EXTRUSIVE ANTIFUNGAL AGENTS

Invasive fungal infections have a high morbidity, death, and economic cost. In recent times, an increasing frequency of fungal infection and antifungal resistance is occurring, prompting the development of innovative antifungal medicines. [23] Fungal complications affect a large number of people around the world, leading to higher hospitalizations and death rates, and the demand for innovative antifungals is rising with the emergence of resistance and immunocompromised individuals. Fungi-related illnesses impact more than a billion people globally, with more than 150 million having severe, life-threatening conditions, resulting in nearly 1.7 million deaths each year. [23] Fungi produce a variety of diseases in humans, ranging from allergy syndromes to superficial, disfiguring, and life-threatening

invasive fungal infections (IFDs), which impact over a billion people globally. [24] Candidiasis is the most common fungal illness among immunocompromised patients. *Candida parapsilosis*, a non-albicans *Candida* species, has emerged as a serious disease. *Candida parapsilosis* is one of the non-albicans *Candida* species that has become a serious problem. The human skin is commensal with *C. parapsilosis*. It can be primarily observed in the alimentary canal, surfaces of mucous membranes, and cuticles in addition to the dermis. The primary antifungals employed for curing candidiasis are azole prescribed drugs and echinocandins. In accordance with Chinese fungal therapy principles, antifungal medication prescription is strictly limited and necessitates the supervision of a physician or above. Fluconazole, voriconazole, itraconazole, amphotericin, caspofungin, garlicin pills, and sodium bicarbonate mouthwash are some of the medicines used for antifungal purposes. [25]

In 1944, Woolley reported that Benzimidazole was the first azole to exhibit antifungal action. However, it wasn't until 1958 that an azole antifungal medication was invented. [26] The demand for azole chemicals for antifungal drugs began when chlormidazole was introduced to the market. [27] Immediately after the development of novel azoles, three new antifungal azoles emerged as topical agents: econazol in 1974, Janssen's miconazole concurrently, and Bayer AG's clotrimazole in 1969. Miconazole is known to be effective in treating vulvovaginal candidiasis, oropharyngeal candidiasis, tinea corporis, tinea pedis, and tinea cruris. [28] When ketoconazole was first released in 1981, it has been identified as a second-generation imidazole. [29] This molecule was the first azole to be made available orally to treat systemic fungal infections, and despite the other imidazoles, its effects were not only effective in treating superficial mycoses. [30] The FDA suggests that clotrimazole is secure and efficient in treating and preventing cutaneous, vulvovaginal, oropharyngeal, and other superficial dermatological infections. The Food and Drug Administration has granted approval for luliconazole, the recently introduced first-generation azole, which has a special vinyl-imidazole structure. *Trichophyton rubrum*, *Microsporum gypseum*, and *Epidermophyton floccosum* are among the dermatophytes that it has a broad-spectrum topical action against. [31]

A next-generation azole (tetrazole), oteseconazole is more selective for fungal lanosterol 14 α demethylase (CYP51). A new family of antifungal called fosmanogepix blocks the fungal Gwt1 protein, which is necessary for mannoprotein trafficking and attachment to the outer cell wall and cell membrane. [32] Rezafungin is an innovative antifungal echinocandin that contributes chemical similarities with anidulafungin. [33] Similar to other echinocandin antifungals, it breaks down fungal cell walls by preventing β -1,3-D-glucan from being biosynthesised. [34] In 1990, the US Food and Drug Administration (FDA) authorized

fluconazole as the first triazole to treat infections caused by *Candida* and *Cryptococcus* species. A significant worry in recent years has been the registration of isavuconazole, posaconazole, voriconazole, [35] and itraconazole [36] among various fungal species. [37]

The newly formed arylazothiazoles [38] and arylhydrazothiazoles [39] were introduced and their antifungal properties assessed. The thiazole compounds shown strong antifungal potential against *Trichophyton mentagrophytes*, *Microsporum gypseum*, and *Candida albicans* in terms of keratinase activity and ergosterol production. The outcomes were contrasted with the conventional medication, fluconazole. When both side chains were aromatic, the antifungal action was shown to be more potent. Two of the series chemicals demonstrated strong antifungal effects by inhibiting the formation of keratinase and ergosterol. [40]

Reported pharmacological activities of Thiazole derivatives are given in **Supplementary table**.

Fungal ailments that affect agriculture causes significant perennial monetary losses to landowners globally. Plant infections produced by virulent fungus severely impede healthy development of crops, which leads to a major drop in agricultural output and nutritional value. [43] For instance, in areas where wheat is grown, *F. graminearum* leads wheat head blight (Duan et al., 2019)16, while *F. moniliforme* typically leads to corn ear rot, a damaging disease that reduces corn output. Commercial fungicides that are currently the primary means of preventing and controlling phytopathogenic fungus; nevertheless, over usage of these kind of fungicides has resulted in environmental contamination, poisoning, and a surge in drug susceptibility. The rise in microbial susceptibility and many pandemics has created an imperative for new heterocyclic molecules with strong physiological activity. Fungal resistance to biocides was exacerbated by the overuse of antifungal medications. For agrochemical researchers, creating novel lead antifungal chemicals is a clicking and challenging issue. [16]

One of the most widely used classes of heterocycles and antifungal agents are azoles. Because of their biological relevance and structural variety, clubbed azoles have emerged as a desirable option for new antibacterial lead chemicals. [17] Chemical fungicides are essential for plant protection and are regarded as one of the most economical and effective solutions. There are many different kinds of chemical fungicides that have been manufactured and traded over time. Scaffold hopping and bioisosterism are design strategies that can enhance the pharmacological characteristics of lead compounds and lower the possibility of cross-resistance. These tactics were used to optimize the structural framework of lead compounds in the production of pharmaceutical drugs or pesticides. [44]




Figure 11: Structures and approval dates of imidazole antifungal drugs [37, 41]




Figure 12: The structures of some commercialized thiazole fungicides [42]

4 CONCLUSION

In conclusion, thiazole derivatives have emerged as a cornerstone in the realm of organic and medicinal chemistry, attributed to their broad spectrum of biological activities. These compounds exhibit significant antimicrobial, anticancer, antitubercular, anti-inflammatory, and antioxidant properties, along with various other therapeutic applications. Their multifunctionality and structural versatility have rendered them indispensable in the design and development of innovative pharmaceutical agents. Furthermore, thiazole derivatives have been utilized in various diagnostic and therapeutic tools, underscoring their relevance beyond conventional drug development.

Despite considerable progress in the synthesis and application of thiazole-based compounds, there remains immense potential for further exploration. Advances in synthetic methodologies, including green chemistry approaches and combinatorial synthesis, can unlock new structural variants with enhanced bioactivity and reduced toxicity. Additionally, the integration of computational techniques such as molecular docking, quantitative structure-activity relationship (QSAR) analysis, and machine learning can expedite the identification of novel thiazole derivatives with targeted pharmacological effects.

Given their unparalleled biological significance, thiazole derivatives continue to attract significant attention from medicinal, synthetic, and pharmacological chemists. Future research endeavours are expected to expand their applications in emerging fields such as nanomedicine, targeted drug delivery, and theranostics, solidifying their position as a dynamic and promising class of compounds in heterocyclic chemistry and modern medicinal research.

REFERENCES

- 1) P. M. Jadhav, S. Kantevari, A. B. Tekale, S. V. Bhosale, R. P. Pawar, and S. U. Tekale, A review on biological and medicinal significance of thiazoles, *Phosphorus, Sulfur, and Silicon and the Related Elements*, 196, 10, 879 (2021) URL <https://doi.org/10.1080/10426507.2021.1945601>.
- 2) N. Siddiqui, M. F. Arshad, W. Ahsan, and M. S. Alam, Thiazoles: A valuable insight into the recent advances and biological activities, *International Journal of Pharmaceutical Sciences and Drug Research*, 1, 3, 136 (2009) URL <https://doi.org/10.25004/IJPSDR.2009.010302>.
- 3) C. B. Mishra, S. Kumari, and M. Tiwari, Thiazole: A promising heterocycle for the development of potent CNS active agents, *European Journal of Medicinal Chemistry*, 92, 1 (2015) URL <https://doi.org/10.1016/j.ejmech.2014.12.031>.
- 4) A. M. Borcea, I. Ionuț, O. Crișan, and O. Oniga, An overview of the synthesis and antimicrobial, antiprotozoal, and antitumor activity of thiazole and bithiazole derivatives, *Molecules*, 26, 3, 1 (2021) URL <https://doi.org/10.3390/molecules26030624>.
- 5) M. F. Arshad, A. Alam, A. A. Alshammari, M. B. Alhazza, I. M. Alziam, M. A. Alam, G. Mustafa, M. S. Ansari, A. M. Alotaibi, and A. A. Alotaibi, Thiazole: A versatile standalone moiety contributing to the development of various drugs and biologically active agents, *Molecules*, 27, 13, 1 (2022) URL <https://doi.org/10.3390/molecules27133994>.
- 6) R. Colorado-Peralta, J. L. Olivares-Romero, S. Rosete-Luna, O. García-Barradas, V. Reyes-Márquez, D. Hernández-Romero, and D. Morales-Morales, Copper-Coordinated Thiazoles and Benzothiazoles: A Perfect Alliance in the Search for Compounds with Antibacterial and Antifungal Activity, *Inorganics*, 11, 5, 1 (2023) URL <https://doi.org/10.3390/inorganics11050185>.
- 7) S. Soliman, A. Soliman, K. Alzoubar, J. Merza, and A. Alasmi, Systematic Review on Thiazole Compounds as Nanoparticles: Chemistry, Synthesis, Antimicrobial Activities, Therapeutic Investigation, *Nanosistemi, Nanomateriali, Nanotehnologii*, 21, 209 (2023) URL https://www.imp.kiev.ua/nanosys/media/pdf/2023/1/nano_vol21_iss1_p0209p0232_2023.pdf.
- 8) S. I. Eissa, A. M. Farrag, S. Y. Abbas, M. F. Shehry, A. Ragab, E. A. Fayed, and Y. A. Ammar, Novel structural hybrids of quinoline and thiazole moieties: Synthesis and evaluation of antibacterial and antifungal activities with molecular modeling studies, *Bioorganic Chemistry*, 110, 104803 (2021) URL <https://doi.org/10.1016/j.bioorg.2021.104803>.
- 9) O. I. El-Sabbagh, M. M. Baraka, S. M. Ibrahim, C. Pannecouque, G. Andrei, R. Snoeck, J. Balzarini, and A. A. Rashad, Synthesis and antiviral activity of new pyrazole and thiazole derivatives, *European Journal of Medicinal Chemistry*, 44, 9, 3746 (2009) URL <https://doi.org/10.1016/j.ejmech.2009.03.038>.
- 10) M. E. D. Francesco, G. Dessole, E. Nizi, P. Pace, U. Koch, F. Fiore, S. Pesci, J. D. Muzio, E. Monteagudo, M. Rowley, and V. Summa, Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1, 3-thiazole as a P4 carbamate replacement, *Journal of medicinal chemistry*, 52, 22, 7014 (2009) URL <https://doi.org/10.1021/jm900524b>.
- 11) K. R. W. Ngoei, D. C. H. Ng, P. R. Gooley, D. P. Fairlie, M. J. Stoermer, and M. A. Bogoyevitch, Identification and characterization of bi-thiazole-2, 2'-diamines as kinase inhibitory scaffolds, *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*, 1834, 6, 1077 (2013) URL <https://doi.org/10.1016/j.bbapap.2013.02.001>.
- 12) D. Huang, M. Liao, T. Zhang, S. You, Y. F. Zhou, and Y. X. Cheng, Design, Synthesis and Fungicidal Activity of Novel 2-aryl-thiazole Derivatives Containing Saccharin Motif, *Chemistry Select*, 5, 42, 13179 (2020) URL <https://doi.org/10.1002/slct.202003616>.
- 13) G. M. Reddy, J. R. Garcia, V. H. Reddy, A. M. De Andrade, A. Camilo, R. A. P. Ribeiro, and S. R. De Lazaro, Synthesis, antimicrobial activity and advances in structure-activity relationships (SARs) of novel tri-substituted thiazole derivatives, *European Journal of Medicinal Chemistry*, 123, 508 (2016) URL <https://doi.org/10.1016/j.ejmech.2016.07.062>.
- 14) K. B. Gangurde, R. A. More, V. A. Adole, and D. S. Ghotekar, Design, synthesis and biological evaluation of new series of benzotriazole-pyrazole clubbed thiazole hybrids as bioactive heterocycles: Antibacterial, antifungal, antioxidant, cytotoxicity study, *Journal of Molecular Structure*, 1299, 136760 (2024) URL <https://doi.org/10.1016/j.molstruc.2023.136760>.
- 15) Z. Xu, X. Cheng, H. Cui, L. Cao, Y. Song, X. Chang, and X. Lv, Design, selective synthesis and biological activities evaluation of novel thiazol-2-ylbenzamide and thiazole-2-ylbenzimidoyl chloride derivatives, *Bioorganic Chemistry*, 107, 333–107,333 (2024).
- 16) N. N. Soliman, M. A. E. Salam, A. A. Fadda, and M. Abdel-Motaal, Synthesis, Characterization, and Biochemical Impacts of Some New Bioactive Sulfonamide Thiazole Derivatives as Potential Insecticidal Agents against the Cotton Leafworm, *Spodoptera littoralis*, *Journal of agricultural and food chemistry*, 68, 21, 5790 (2020) URL <https://doi.org/10.1021/acs.jafc.9b06394>.
- 17) A. Biernasiuk, A. Berecka-Rycerz, A. Gumieniczek, M. Malm, K. Z. Łączkowski, J. Szymańska, and A. Malm, The newly synthesized thiazole derivatives as potential antifungal compounds against *Candida albicans*, *Applied Microbiology and Biotechnology*, 105, 16-17, 6355 (2021) URL <https://doi.org/10.1007/s00253-021-11477-7>.
- 18) M. A. Salem, S. Y. Abbas, M. A. El-Sharief, M. H. Helal, M. A. Gouda, M. A. Assiri, and T. E. Ali, Novel Structural Hybrids of Pyrrole and Thiazole Moieties: Synthesis and Evaluation of Antibacterial and Antifungal Activities, *Acta Chimica Slovenica*, 68, 4, 990 (2021) URL <https://doi.org/10.17344/acsi.2021.6980>.
- 19) T. H. Namitha, S. S. Nair, A. Kumar, B. Vinod, and P. A. Daisy, A review on synthesis and biological activity of thiazole and its derivatives, *International Journal of Pharmaceutical Sciences Research*, 70, 1, 189 (2021) URL <https://globalresearchonline.net/journalcontents/v70-1/29.pdf>.

- 20) V. J. Ram, A. Sethi, M. Nath, and R. Pratap, *The Chemistry of Heterocycles: Nomenclature and Chemistry of Three-to-Five Membered Heterocycles*, Elsevier (2019)URL <https://doi.org/10.1016/C2015-0-05990-1>.
- 21) I. H. A. Ripain and N. Ngah, A brief review on the thiazole derivatives: Synthesis methods and biological activities, *Malaysian Journal of Analytical Sciences*, 25, 2, 257 (2021)URL https://mjas.analis.com.my/mjas/v25_n2/pdf/Hasanah_25_2_8.pdf.
- 22) J. J. Li, Cook-Heilbron thiazole synthesis, *Name Reactions*, 82–82, Springer, Berlin, Heidelberg (2003)URL https://doi.org/10.1007/978-3-662-05336-2_66.
- 23) A. G. Stewart and D. L. Paterson, How urgent is the need for new antifungals? *Expert Opinion on Pharmacotherapy*, 22, 14, 1857 (2021)URL <https://doi.org/10.1080/14656566.2021.1935868>.
- 24) M. M. Teixeira, D. T. Carvalho, E. Sousa, and E. Pinto, New Antifungal Agents with Azole Moieties, *Pharmaceuticals*, 15, 11, 1 (2022)URL <https://dx.doi.org/10.3390/ph15111427>.
- 25) Y. N. Ruma, M. V. Keniya, J. D. A. Tyndall, and B. C. Monk, Characterisation of Candida parapsilosis CYP51 as a Drug Target Using Saccharomyces cerevisiae as Host, *Journal of Fungi*, 8, 1, 1 (2022)URL <https://dx.doi.org/10.3390/jof8010069>.
- 26) D. W. Woolley, Some biological effects produced by benzimidazole and their reversal by purines, *Journal of Biological Chemistry*, 152, 2, 225 (1944)URL [https://doi.org/10.1016/S0021-9258\(18\)72045-0](https://doi.org/10.1016/S0021-9258(18)72045-0).
- 27) H. Zhang and A. Zhu, Emerging Invasive Fungal Infections: Clinical Features and Controversies in Diagnosis and Treatment Processes, *Infection and Drug Resistance*, 13, 607 (2020)URL <https://doi.org/10.2147/IDR.S237815>.
- 28) R. A. Fromtling, Overview of medically important antifungal azole derivatives, *Clinical Microbiology Reviews*, 1, 2, 187 (1988)URL <https://doi.org/10.1128/cmr.1.2.187>.
- 29) P. A. Regidor, M. Thamkhantho, C. Chayachinda, and S. Palacios, Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature, *Journal of Obstetrics and Gynaecology*, 43, 1, 1 (2023)URL <https://doi.org/10.1080/01443615.2023.2195001>.
- 30) C. Sheng and W. Zhang, New Lead Structures in Antifungal Drug Discovery, *Current Medicinal Chemistry*, 18, 5, 733 (2011)URL <https://dx.doi.org/10.2174/092986711794480113>.
- 31) D. Khanna and S. Bharti, Luliconazole for the treatment of fungal infections: an evidence-based review, *Core Evidence*, 113, 113 (2014)URL <https://dx.doi.org/10.2147/ce.s49629>.
- 32) S. Brand, T. Degenhardt, P. Nyirjesy, J. Sobel, C. Handelsman, K. Person, R. Schotzinger, and A. Tavakkol, To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC), *American Journal of Obstetrics and Gynecology*, 215, 6, PS821 (2016)URL <https://dx.doi.org/10.1016/j.ajog.2016.09.016>.
- 33) S.-Q. Wang, Y.-F. Wang, and Z. Xu, Tetrazole hybrids and their antifungal activities, *European Journal of Medicinal Chemistry*, 170, 225 (2019)URL <https://dx.doi.org/10.1016/j.ejmech.2019.03.023>.
- 34) N. P. Wiederhold, The antifungal arsenal: alternative drugs and future targets, *International journal of antimicrobial agents*, 51, 3, 333 (2018)URL <https://doi.org/10.1016/j.ijantimicag.2017.09.002>.
- 35) J. A. Maertens, History of the development of azole derivatives, *Clinical Microbiology and Infection*, 10, Suppl 1, 1 (2004)URL <https://doi.org/10.1111/j.1470-9465.2004.00841.x>.
- 36) M. V. Castelli, E. Butassi, M. C. Monteiro, L. A. Svetaz, F. Vicente, and S. A. Zacchino, Novel antifungal agents: a patent review (2011 - present), *Expert Opinion on Therapeutic Patents*, 24, 3, 323 (2014)URL <https://doi.org/10.1517/13543776.2014.876993>.
- 37) M. Shafei, L. Peyton, M. Hashemzadeh, and A. Foroumadi, History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action, *Bioorganic Chemistry*, 104, 104240 (2020)URL <https://dx.doi.org/10.1016/j.bioorg.2020.104240>.
- 38) G. Schellack, P. Harirari, and N. Schellack, B-Complex Vitamin Deficiency and Supplementation, *South African Pharmaceutical Journal*, 82, 4, 28 (2015)URL https://www.researchgate.net/publication/283556727_B-complex_vitamin_deficiency_and_supplementation.
- 39) J. Neves, R. P. Marinho, N. R. D. L. L. Martins, P. K. De Araujo, and J. Lucciola, Prolonged Septicaemic Salmonellosis: Treatment of Intercurrent Schistosomiasis with Niridazole, *Transactions of the Royal Society of Tropical Medicine & Hygiene*, 63, 1, 79 (1969)URL [https://doi.org/10.1016/0035-9203\(69\)90070-4](https://doi.org/10.1016/0035-9203(69)90070-4).
- 40) S. A. Ouf, S. M. Gomha, M. Eweis, A. S. Ouf, and I. A. Sharawy, Efficiency of Newly Prepared Thiazole Derivatives against Some Cutaneous fungi, *Bioorganic & Medicinal Chemistry*, 26, 12, 3287 (2018)URL <https://doi.org/10.1016/j.bmc.2018.04.056>.
- 41) R. K. Scher, N. Nakamura, and A. Tavakkol, Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis, *Mycoses*, 57, 7, 389 (2014)URL <https://dx.doi.org/10.1111/myc.12168>.
- 42) T. Zhang, C. Yuan, Q. Zhou, H. Xin, Y. Liu, J. Tian, and W. Xue, Chalcone derivatives containing thiazole fragment: Synthesis and antifungal activity, *Journal of Saudi Chemical Society*, 27, 6, 1 (2023)URL <https://doi.org/10.1016/j.jscs.2023.101773>.
- 43) J. R. Perfect and M. Ghannoum, Emerging issues in antifungal resistance, *Infectious Disease Clinics of North America*, 34, 4, 921 (2020)URL <https://doi.org/10.1016/j.idc.2020.05.003>.
- 44) G. Yang, L. Shi, Z. Pan, L. Wu, L. Fan, C. Wang, C. Xu, and J. Liang, The synthesis of coumarin thiazoles containing a trifluoromethyl group and their antifungal activities, *Arabian Journal of Chemistry*, 14, 1, 1 (2021)URL <https://dx.doi.org/10.1016/j.arabjc.2020.10.027>.